These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The impact of possible modifications to the DS86 dosimetry on neutron risk and relative biological effectiveness. Hunter N; Charles MW J Radiol Prot; 2002 Dec; 22(4):357-70. PubMed ID: 12546224 [TBL] [Abstract][Full Text] [Related]
3. Choice of model and uncertainties of the gamma-ray and neutron dosimetry in relation to the chromosome aberrations data in Hiroshima and Nagasaki. Rühm W; Walsh L; Chomentowski M Radiat Environ Biophys; 2003 Jul; 42(2):119-28. PubMed ID: 12844221 [TBL] [Abstract][Full Text] [Related]
4. Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates. Preston DL; Pierce DA; Shimizu Y; Cullings HM; Fujita S; Funamoto S; Kodama K Radiat Res; 2004 Oct; 162(4):377-89. PubMed ID: 15447045 [TBL] [Abstract][Full Text] [Related]
5. Neutron relative biological effectiveness in Hiroshima and Nagasaki atomic bomb survivors: a critical review. Sasaki MS; Endo S; Hoshi M; Nomura T J Radiat Res; 2016 Nov; 57(6):583-595. PubMed ID: 27614201 [TBL] [Abstract][Full Text] [Related]
6. Neutrons at Hiroshima: how their disappearance affected risk estimates. Ellett WH Radiat Res; 1991 Oct; 128(1 Suppl):S147-52. PubMed ID: 1924742 [TBL] [Abstract][Full Text] [Related]
7. Estimates of neutron relative biological effectiveness derived from the Japanese atomic bomb survivors. Little MP Int J Radiat Biol; 1997 Dec; 72(6):715-26. PubMed ID: 9416794 [TBL] [Abstract][Full Text] [Related]
8. Cytogenetic validation of DS02R1-estimated dose for atomic bomb survivors in Hiroshima and Nagasaki with FISH. Kodama Y; Nakamura N; Nakano M; Ohtaki K; Hamasaki K; Noda A Int J Radiat Biol; 2024; 100(8):1155-1164. PubMed ID: 38991111 [TBL] [Abstract][Full Text] [Related]
9. The effect of changes in dosimetry on cancer mortality risk estimates in the atomic bomb survivors. Preston DL; Pierce DA Radiat Res; 1988 Jun; 114(3):437-66. PubMed ID: 3375435 [TBL] [Abstract][Full Text] [Related]
10. Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: Part 1. Comparison of risk coefficients for site-specific cancer mortality based on the DS86 and T65DR shielded kerma and organ doses. Shimizu Y; Kato H; Schull WJ; Preston DL; Fujita S; Pierce DA Radiat Res; 1989 Jun; 118(3):502-24. PubMed ID: 2727272 [TBL] [Abstract][Full Text] [Related]
11. Fetal atomic bomb survivor dosimetry using the J45 series of pregnant female phantoms with realistic survivor exposure scenarios: comparisons to dose estimates in the DS02 system. Paulbeck CJ; Sato T; Funamoto S; Lee C; Griffin KT; Cullings HM; Egbert SD; Endo A; Hertel NE; Bolch WE Radiat Environ Biophys; 2023 Aug; 62(3):317-329. PubMed ID: 37296237 [TBL] [Abstract][Full Text] [Related]
12. The effects of neutrons in Hiroshima. Implications for the risk estimates. Kellerer AM C R Acad Sci III; 1999; 322(2-3):229-37. PubMed ID: 10196677 [TBL] [Abstract][Full Text] [Related]
13. Effective dose of A-bomb radiation in Hiroshima and Nagasaki as assessed by chromosomal effectiveness of spectrum energy photons and neutrons. Sasaki MS; Endo S; Ejima Y; Saito I; Okamura K; Oka Y; Hoshi M Radiat Environ Biophys; 2006 Jul; 45(2):79-91. PubMed ID: 16807767 [TBL] [Abstract][Full Text] [Related]
14. Radiation-related posterior lenticular opacities in Hiroshima and Nagasaki atomic bomb survivors based on the DS86 dosimetry system. Otake M; Schull WJ Radiat Res; 1990 Jan; 121(1):3-13. PubMed ID: 2300666 [TBL] [Abstract][Full Text] [Related]
15. Workshop Report on Atomic Bomb Dosimetry--Review of Dose Related Factors for the Evaluation of Exposures to Residual Radiation at Hiroshima and Nagasaki. Kerr GD; Egbert SD; Al-Nabulsi I; Bailiff IK; Beck HL; Belukha IG; Cockayne JE; Cullings HM; Eckerman KF; Granovskaya E; Grant EJ; Hoshi M; Kaul DC; Kryuchkov V; Mannis D; Ohtaki M; Otani K; Shinkarev S; Simon SL; Spriggs GD; Stepanenko VF; Stricklin D; Weiss JF; Weitz RL; Woda C; Worthington PR; Yamamoto K; Young RW Health Phys; 2015 Dec; 109(6):582-600. PubMed ID: 26509626 [TBL] [Abstract][Full Text] [Related]
16. Dosimetric Impact of a New Computational Voxel Phantom Series for the Japanese Atomic Bomb Survivors: Methodological Improvements and Organ Dose Response Functions. Sato T; Funamoto S; Paulbeck C; Griffin K; Lee C; Cullings H; Egbert SD; Endo A; Hertel N; Bolch WE Radiat Res; 2020 Oct; 194(4):390-402. PubMed ID: 33045092 [TBL] [Abstract][Full Text] [Related]
17. Late radiation responses in man: current evaluation from results from Hiroshima and Nagasaki. Schull WJ Adv Space Res; 1983; 3(8):231-9. PubMed ID: 11542750 [TBL] [Abstract][Full Text] [Related]
18. Persistent chromosome aberrations in the somatic cells of A-bomb survivors, Hiroshima and Nagasaki. Awa AA J Radiat Res; 1991 Mar; 32 Suppl():265-74. PubMed ID: 1762114 [TBL] [Abstract][Full Text] [Related]
19. Dosimetric Impact of a New Computational Voxel Phantom Series for the Japanese Atomic Bomb Survivors: Pregnant Females. Paulbeck C; Griffin K; Lee C; Cullings H; Egbert SD; Funamoto S; Sato T; Endo A; Hertel N; Bolch WE Radiat Res; 2019 Nov; 192(5):538-561. PubMed ID: 31469615 [TBL] [Abstract][Full Text] [Related]
20. Reassessment of the cancer mortality risk among Hiroshima atomic-bomb survivors using a new dosimetry system, ABS2000D, compared with ABS93D. Katayama H; Matsuura M; Endo S; Hoshi M; Ohtaki M; Hayakawa N J Radiat Res; 2002 Mar; 43(1):53-64. PubMed ID: 12056330 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]